Research reportIntraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
Introduction
The accurate regulation of food intake and body weight depends on the complex interaction of several regulatory systems. Some of these systems appear to act primarily at the level of individual bouts of ingestion or meals. The prototypical compound for such a short-term satiety signal is the gut peptide cholecystokinin (CCK) which is secreted in response to food in the upper intestine. When administered intraperitoneally or directly into the central nervous system (CNS), CCK causes a potent reduction in the size of the subsequent meal [16]. After such treatment, however, total daily food intake is not different from that of controls [22]. This implies that the effect of CCK is short-lived, and that animals eat more in subsequent meals in order to compensate for the lost calories from the reduced first meal in order to maintain daily caloric intake and body weight constant [22]. When CCK is administered at the onset of each spontaneous meal in non-deprived and freely feeding rats, it reliably reduces the size of each meal compared to the meal size of control animals, but daily caloric intake and body weight are unchanged because animals receiving CCK compensate by increasing the number of individual meals they take [22]. Hence, satiety factors such as CCK, if given alone, are unlikely to provide effective therapeutic tools for obesity.
A second category of peptides, including insulin and leptin, act in a fundamentally different manner. When administered continuously into the CNS over days, insulin or leptin produces persistent reductions in daily caloric intake and body weight at doses that have no effect when administered into the periphery 15, 23suggesting that the CNS is the likely target for this action. Since both insulin and leptin are secreted in proportion to body adiposity, each has been considered a likely factor that interacts with meal-generated satiety factors in the long-term control of body adiposity 13, 24. Consistent with this, there is evidence that the administration of small amounts of insulin (and possibly leptin) potentiates the action of meal-generated satiety factors such as CCK [14]. Hence, when an animal loses weight, it secretes less insulin and leptin, and satiety factors such as CCK are rendered less effective. One result is larger meals until weight is restored. The opposite occurs if an animal gains weight. In this way adiposity factors act in concert with satiety factors to coordinate food intake with the maintenance of total body adiposity.
Turton and colleagues have proposed that glucagon-like-peptide-1 (7–36) amide (GLP-1), acting at receptors in the CNS, is an endogenous factor important in the regulation of food intake 17, 19. GLP-1 is secreted from the distal gut in response to the presence of mixed nutrients in the gastrointestinal tract 3, 8. In the periphery, GLP-1 influences glucose homeostasis after ingestion of carbohydrate meals via modulation of gastric emptying and alteration of the secretion of insulin and glucagon from the pancreas [2]. The precursor for GLP-1 (preproglucagon) is also synthesized in the CNS in the nucleus of the solitary tract (NTS) 4, 7, 10. Receptors for GLP-1 are concentrated in the paraventricular nucleus of the hypothalamus (PVN), the amygdala, and several regions of the brainstem including the area postrema and the NTS [5]. In their report, Turton et al. [19]observed that bolus administration of GLP-1 into the third ventricle of lean rats produced a potent and dose-dependent reduction of 2 h food intake, and they further reported that this reduction could be blocked by pretreatment with the specific GLP-1 receptor antagonist, exendin. Based on these findings, they proposed GLP-1 as a natural regulator of food intake and possibly adiposity as well. The purpose of the present experiments was to determine whether central administration of GLP-1 alters long-term food intake and body weight in lean Long–Evans rats and in genetically obese (fa/fa) Zucker rats. We therefore sought to determine whether GLP-1 acts in the CNS as a short-term regulator of food intake, as occurs with CCK, or as a long-term adiposity-type signal such as leptin or insulin.
Section snippets
Animals
Male Long–Evans rats were obtained from the vivarium maintained by the Department of Psychology at the University of Washington; and female fatty Zucker rats (fa/fa) were obtained from Harlan Inc. Rats were individually housed in stainless steel hanging cages (Long Evans) or plexiglass tubs with shavings on the floor (Zuckers). The rooms were maintained on 12:12 h light:dark cycle in a temperature-controlled room. Except where noted, animals were maintained on ad lib water and pelleted chow.
Surgical preparation
Experiment 1
The purpose of this experiment was to determine if single intraventricular (ivt) injections of GLP-1 reduce food intake of Long Evans and of fatty Zucker rats. Data were analyzed with the Student's t-test, with p<0.05 (two-tailed) indicating significance.
In the first hour following injection, Long Evans rats receiving GLP-1 consumed significantly less chow than saline controls (0.7 vs. 2.6 g, p<0.001; Fig. 1, top panel). After 2 and 24 h, intake of the two groups did not differ reliably (2
General discussion
The current results replicate those of Turton et al. [19]demonstrating that when administered into the third ventricle, GLP-1 potently reduces food intake, and that the effect lasts for up to 2 h in lean Long–Evans rats. The current experiments extend the findings of Turton et al. in several important ways. First, when food intake is assessed over longer intervals following bolus injections, the effect of GLP-1 on food intake is found to be short-lived and essentially non-existent after 24 h.
Acknowledgements
These studies were supported by grants from the NIH (DK-17844, DK-35816, DK/NS53287), the Dutch Diabetes Association and the Clinical Nutrition Research Unit at the University of Washington. The Zucker rats were a generous gift of Hoffmann-La Roche Inc.
References (24)
- et al.
Glucagon gene expression in vertebrate brain
J. Biol. Chem.
(1988) - et al.
Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats
Appetite
(1986) - et al.
Cholecystokinin- and dexfenfluramine-induced anorexia compared using devazepide and c-fos expression in the rat brain
Regul. Pept.
(1994) - et al.
Diet composition alters the satiety effect of cholecystokinin in lean and obese Zucker rats
Physiol. Behav.
(1988) - et al.
Central insulin enhances sensitivity to cholecystokinin
Physiol. Behav.
(1995) - et al.
A comparison between the effects of intraventricular insulin and intraperitoneal LiCl on three measures sensitive to emetic agents
Behav. Neurosci.
(1995) - et al.
Elimination of the action of Glucagon-like Peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy humans
J. Clin. Investigation
(1996) - et al.
Response of GLP-1 to nutrients in humans
Digestion
(1993) - et al.
Distribution of GLP-1 binding sites in the rat brain: evidence that exendin is a ligand of brain GLP-1 sites
Eur. J. Neurosci.
(1995) - I. Gunn, T. Humby, J. Herbert, J.M. Polak, S.R. Bloom, D. O'Shea, Glucagon-like peptide-1 in models of abnormal feeding...
Cellular localization of proglucagon/glucagon-like peptide 1 messenger RNAs in rat brain
J. Neurosci.
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
Digestion
Cited by (116)
Glucagon-like peptide 1 (GLP-1)
2019, Molecular MetabolismCitation Excerpt :However, vagal afferents and vagal afferent GLP-1 receptors are presumably less important for the effects of peripheral GLP-1 on body mass. The acute anorectic effect of centrally administered GLP-1 was described simultaneously 1996 by Steve Bloom's group [668] and by Mads Tang-Christensen et al. [92] and was confirmed by others [667,698]. In mice and rats, the short-term inhibition of food intake induced by i.c.v. administered GLP-1R agonists is dose-dependent, can be blocked by pretreatment with exendin (9–39) [668,698] and is absent in GLP-1R KO mice [690].
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
2019, Neurochemistry InternationalCitation Excerpt :Although it is best known for its incretin effect, GLP-1 also exerts a potent effect on feeding behavior to control nutrient intake. Early studies utilized intracerebroventricular injections to show that exogenous modulation of GLP-1 action could dose dependently increase (through antagonism) (Meeran et al., 1999) or decrease (through agonism) (Donahey et al., 1998; Tang-Christensen et al., 1996; Turton et al., 1996) food intake in rodents. Intravenous infusions of synthetic GLP-1 also reduced food intake and subjective reporting of hunger in human participants (Gutzwiller et al., 1999).
Evolution of the glucagon-like system across fish
2018, General and Comparative EndocrinologyEstradiol modulates the anorexic response to central glucagon-like peptide 1
2017, Hormones and BehaviorAdvances in the surgical treatment of morbid obesity
2013, Molecular Aspects of MedicineCitation Excerpt :As an incretin, this molecule participates in crosstalk between the gut and pancreas, with the main action of GLP-1 to stimulate insulin secretion from pancreatic beta cells (Fehmann et al., 1995). However, GLP-1 is also known to act in the CNS to inhibit appetite (Donahey et al., 1998). GLP-1 release depends on nutrient delivery to the hindgut (Herrmann et al., 1995; Layer et al., 1995).